Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
In recent years, there has been a significant shift towards the use of advanced immunotherapy techniques for the treatment of various diseases, including autoimmune diseases. Among these innovative therapies, Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a promising approach, particularly in the field of cancer treatment. However, the potential application of CAR-T cells in autoimmune diseases has also gained attention due to their ability to target specific autoimmune responses within the body. Leveraged by years of experience, Creative Biolabs has developed the CellRapeutics™ CART development service aimed at addressing autoimmune diseases through cutting-edge CAR-T cell technology.
CAR therapy strategies targeting autoimmune diseases focus on different items, including leveraging the specificity and efficacy of CAR-T cells to target and eliminate pathological immune cells responsible for autoimmune responses. The development of CAR-T cells to deplete autoreactive B or T cells, as well as other accessory antigen-presenting cells, has also shown promising outcomes in diseases characterized by excessive autoantibody levels or hyperactive lymphocyte numbers. In addition, the incorporation of immunosuppressive regulatory T cells (Tregs) into CAR-T therapy has further enhanced the potential for successful treatment of autoimmune diseases by restoring immune tolerance and balance within the body. By optimizing the structure and function of CARs based on experience from cancer treatment, Creative Biolabs aims to maximize the therapeutic potential of CAR-T cells for autoimmune conditions.
Fig.1 CAR therapeutic strategies for autoimmune diseases.1
Creative Biolabs is dedicated to providing high-quantity CellRapeutics™ CART development service tailored specifically for autoimmune diseases. Our customized services cover a full range of services for CAR-T therapy development for autoimmune diseases, including the biomarker identification and selection to preclinical in vivo assay.
Fig.2 CellRapeutics™ CART Development Services.
Q1: What are the challenges of CAR-based therapies for autoimmune diseases?
A1: While CAR-based therapies have shown significant promise in the treatment of autoimmune diseases, there are also many limitations and challenges that need to be addressed for their successful implementation. One main limitation is the complexity and heterogeneity of immune dysregulation mechanisms in autoimmune diseases, which can present challenges in targeting specific cells or pathways effectively. Another limitation lies in the potential off-target effects and unintended immune responses that may arise from CAR-based therapies targeting autoimmune diseases. Ensuring the specificity of CAR-T cells to avoid detrimental effects on healthy tissues is crucial for the safety and efficacy of these treatments.
Through a combination of specialized services, innovative technologies, and dedication to scientific excellence, Creative Biolabs is committed to providing advanced immunotherapy solutions for autoimmune diseases. If you would like to learn more about our services, please feel free to contact our technical team.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
